# EMERGING FRONTIERS: AGING, AUTOIMMUNITY, LONG COVID

**Chapter Length**: 7 minutes
**Topics**: TRIP study [aging), SLE trials, Long COVID hypothesis, future vision

---

MARCUS [excited] So we've seen how sirolimus transformed care for TSC, LAM, vascular anomalies, and Castleman's disease. But now researchers are asking an even bigger question: what if mTOR dysregulation is involved in aging itself?

ELENA [curious] Wait—aging? As in, getting old?

MARCUS [passionate] Yes! One of the hallmarks of aging is chronic, low-grade inflammation—sometimes called 'inflammaging.' And mTOR hyperactivation is thought to contribute to that. When mTOR is overactive in older adults, immune function declines, metabolism shifts, and the risk of age-related diseases increases.

ELENA [intrigued] So if you could dial down mTOR activity in older adults, you might improve immune function and slow some aspects of aging?

MARCUS [excited] That's the hypothesis. And Matt Kaeberlein at the University of Washington led a trial to test it—the TRIP study. Targeting Aging with Rapamycin in Humans.

ELENA [curious] What did they do?

MARCUS [thoughtful] They enrolled healthy older adults—ages 65 and up—and randomized them to low-dose rapamycin or placebo. The primary endpoint was flu vaccine response. The idea was: if rapamycin improves immune function, older adults should mount a stronger response to the flu vaccine.

ELENA [hopeful] And?

MARCUS [passionate] The rapamycin group had significantly improved vaccine responses compared to placebo. This was published in Geroscience in 2023. It's the first human evidence that low-dose rapamycin might enhance healthspan—the number of years spent in good health.

ELENA [reflective] That's remarkable. But I imagine there are concerns. You're giving a drug to healthy people.

MARCUS [thoughtful] Absolutely. The dose used in TRIP was much lower than the doses used for TSC or LAM—designed to minimize side effects while still hitting the mTOR target. But long-term safety in healthy aging populations isn't established yet. This is early-stage research.

ELENA [curious] So we're not ready to prescribe rapamycin as a longevity drug?

MARCUS [warm] Not yet. But the TRIP study opens the door. If larger trials confirm that low-dose rapamycin improves immune function, reduces frailty, or extends healthspan without significant toxicity, it could become a paradigm-shifting intervention.

ELENA [hopeful] Okay, so that's aging. What about autoimmunity? You mentioned lupus earlier.

MARCUS [excited] Yes! Systemic lupus erythematosus—SLE—is an autoimmune disease where the immune system attacks the body's own tissues. And recent research shows that mTOR is overactive in lupus patients. Specifically, T cells in lupus have dysregulated mTOR signaling.

ELENA [intrigued] So if you inhibit mTOR, you might dampen the autoimmune response?

MARCUS [passionate] Exactly. Small case series have shown that sirolimus can reduce lupus disease activity in some patients. And now there are prospective trials testing sirolimus in SLE, as well as in other autoimmune conditions like Sjögren's syndrome.

ELENA [curious] Is this being pursued seriously? Could sirolimus become an approved treatment for lupus?

MARCUS [thoughtful] It's possible. But lupus is complex. There are multiple pathways involved, and not all patients will respond to mTOR inhibition. What we're learning is that precision medicine in autoimmunity means identifying which patients have mTOR dysregulation and targeting them specifically.

ELENA [reflective] So the lesson isn't 'sirolimus works for lupus.' It's 'sirolimus works for lupus patients with mTOR hyperactivation.'

MARCUS [warm] Exactly. That's precision medicine in action.

ELENA [curious] Alright, now let's talk about Long COVID. Because millions of people are dealing with persistent symptoms after COVID-19 infection. How does sirolimus fit in?

MARCUS [passionate] Long COVID—or post-acute sequelae of SARS-CoV-2—is still being understood. But some patients have persistent viral replication, T cell exhaustion, and chronic inflammation. And there's emerging evidence that mTOR hyperactivation might be contributing to immune dysfunction in those patients.

ELENA [intrigued] So the hypothesis is that sirolimus could restore T cell function and help clear viral reservoirs?

MARCUS [excited] Yes! There are active clinical trials at Yale, Mount Sinai, and other centers testing sirolimus in Long COVID patients with evidence of persistent viral markers or immune exhaustion. The idea is that by inhibiting mTOR, you might enhance autophagy—the cellular recycling process—and help the immune system clear lingering viral particles.

ELENA [hopeful] That could help millions of people.

MARCUS [thoughtful] It could. But we need to see the trial results. Long COVID is heterogeneous—there are probably multiple subtypes with different mechanisms. Sirolimus might work for some patients but not others.

ELENA [reflective] So once again, it's about understanding mechanism and targeting the right patients.

MARCUS [warm] Exactly. And that's the thread running through this entire story. Whether it's TSC, LAM, vascular anomalies, Castleman's disease, aging, lupus, or Long COVID—the key is identifying where mTOR is dysregulated and targeting it rationally.

ELENA [curious] Marcus, let me ask you this. We've now covered nearly a dozen different applications of sirolimus. Does that seem incredible to you? That one drug can do so much?

MARCUS [passionate] It does. But it also makes perfect sense. mTOR is a fundamental regulator of cell growth, metabolism, and immune function. It's involved in so many biological processes that when it goes wrong, the consequences are widespread. And that means a drug that targets mTOR can have equally widespread benefits.

ELENA [thoughtful] But here's what I find striking. Sirolimus was discovered by accident. On Easter Island. By a scientist collecting soil samples. Nobody set out to find a drug that could treat aging or Long COVID.

MARCUS [reverential] That's true. And it's a reminder that great science often begins with curiosity, not directed planning. Suren Sehgal didn't know what rapamycin would become. He just knew it was interesting. And he refused to let it die.

ELENA [hopeful] And 50 years later, we're still discovering what it can do.

MARCUS [excited] We are. And I think that's the real lesson of the sirolimus story. When you understand mechanism—when you follow the molecular thread—you unlock possibilities that nobody imagined.

ELENA [reflective] So what's next? Are there other diseases where sirolimus might work?

MARCUS [passionate] Almost certainly. Researchers are looking at mTOR in neurodegenerative diseases, in metabolic disorders, in cancer subtypes. Every time we find a disease with mTOR dysregulation, sirolimus becomes a candidate therapy.

ELENA [curious] And what about other drugs? If sirolimus can be repurposed for so many conditions, what other molecules are sitting in pharmacy cabinets waiting to be rediscovered?

MARCUS [warm] That's the question driving the entire field of drug repurposing. How many other Easter Island soil samples are out there? How many other Suren Sehgals? How many other David Fajgenbams?

ELENA [hopeful] Let's find out. But first, let's close this story. Let's reflect on what sirolimus teaches us about science, medicine, and the power of persistence.

---

**Timing**: ~7 minutes
